Review of risk evaluation scores for benign end stage liver diseases recipients.
10.3760/cma.j.cn112139-20211216-00607
- VernacularTitle:终末期良性肝病肝移植受者预后评分系统的研究进展
- Author:
Ping Bo JIN
1
;
Wei Li WANG
1
;
Yun Tao ZHANG
1
;
Nan MA
1
;
Xue Li BAI
1
;
Wei ZHANG
1
;
Ting Bo LIANG
1
Author Information
1. Department of Hepatic-biliary-pancreatic Surgery,First Affiliated Hospital of Zhejiang University,Hangzhou 310003,China.
- Publication Type:Review
- MeSH:
Acute-On-Chronic Liver Failure;
End Stage Liver Disease/surgery*;
Humans;
Liver Transplantation;
Prognosis;
Retrospective Studies;
Severity of Illness Index
- From:
Chinese Journal of Surgery
2022;60(4):396-400
- CountryChina
- Language:Chinese
-
Abstract:
Liver transplant is an unreplaceable method for benign end-stage liver disease. The risk evaluation for the waiting list recipients and for post-transplant survival could provide practical indication for organ allocation. In recent years, there are two major kinds of evaluation scores. The first kind of evaluation scores is based on model for end-stage liver disease(MELD) score,including SOFT/P-SOFT score,UCLA-FRS score and BAR score. The other evaluation system is based on the concept of acute-on-chronic liver failure,including CLIF-C-ACLF score,TAM score,AARC-ACLF score and COSSH-ACLF score. The scores based on ACLF have been shown superior power in predicting waiting list survival and post-transplant prognosis than MELD. This article reviews the two kinds of evaluation scores,aiming for the better allocation policy and the better prognosis of benign end-stage liver disease.
